

Docket No.: 066783-0145

07/14/05

PATENT

DAE
\$
JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Pulst, Stefan M., et al.
Appl. No. : 10/782,375
Filed : February 18, 2004
Title : PARKIN INTERACTING POLYPEPTIDES
AND METHODS OF USE
Grp./A.U. : 1645
Examiner : Not Yet Assigned

Customer No.: 41552
Confirmation No.: 3578
CERTIFICATE OF MAILING BY EXPRESS MAIL(37
CFR § 1.10)
"Express Mail" Mailing Label Number EV643842954US
I hereby certify that this paper or fee is being deposited with the
United States Postal Service "Express Mail Post Office to
Addressee" service under 37 CFR § 1.10 on the date indicated
above and is addressed to Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450 on Jul 12, 2005.

Sarah Nunez

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is a Petition for Revival of an Application for Patent Abandoned Unintentionally.

- ☒ Applicant is entitled to small entity status under 37 CFR 1.27.
☒ Also attached: Copy of the response to Missing Parts as originally filed on October 8, 2004; Copy of Notice of Abandonment

The fee has been calculated as shown below:

	NO. OF CLAIMS	HIGHEST PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	FEE
Total Claims	10	25	0	\$25.00 =	\$0.00
Independent Claims	1	4	0	\$100.00 =	\$0.00
Multiple dependent claims newly presented					\$0.00
Fee for Petition to Revive					\$750.00
Total of Above Calculations					\$750.00

- ☒ Please charge my Deposit Account No. 502624 in the amount of \$750.00. An additional copy of this transmittal sheet is submitted herewith.
- ☒ The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment, to Deposit Account No. 502624, including any filing fees under 37 CFR 1.16 for presentation of extra claims and any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,


MCDERMOTT WILL & EMERY LLP

Deborah L. Cadena

Deborah L. Cadena

Registration No. 44,048

4370 La Jolla Village Drive, Suite 700
San Diego, CA 92122
858.535.9001 DLC:mls
Facsimile: 858.597.1585
Date: July 5, 2005



Docket No.: 066783-0145

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Pulst, Stefan M., et al.
Appl. No. : 10/782,375
Filed : February 18, 2004
Title : PARKIN INTERACTING
POLYPEPTIDES AND METHODS
OF USE

Grp./A.U. : 1645
Examiner: : Not Yet Assigned

Customer No.: 41552

Confirmation No.: 3578

CERTIFICATE OF MAILING BY EXPRESS MAIL(37
CFR § 1.10)

"Express Mail" Mailing Label Number EV643842954US

I hereby certify that this paper or fee is being deposited with
the United States Postal Service "Express Mail Post Office to
Addressee" service under 37 CFR § 1.10 on the date indicated
above and is addressed to Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450 on Jul 12, 2005.

Sarah Nunez

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED
UNINTENTIONALLY UNDER 37 C.F.R. §1.137(b)**

The above-identified application became abandoned because the response to Missing Parts was not timely received by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the Office notice or action plus any extensions of time actually obtained.

Applicants hereby petition for revival of this application. Since this application was filed on February 18, 2004, no terminal disclaimer is required.

The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 C.F.R. 1.137(b) was unintentional.

The petition fee of \$750.00 required by 37 C.F.R. § 1.17(m) is enclosed herewith. Please charge my Deposit Account No. 502624 in the amount of \$750.00 to cover the petition fee.

07/15/2005 MAHMED1 00000049 502624 10782375


01 FC:2453 750.00 DA

Serial No. 10/782,375

Applicants are simultaneously filing a copy of the response to Missing Parts as originally filed on October 8, 2004.

Respectfully submitted,

MCDERMOTT WILL & EMERY LLP



Deborah L. Cadena

Registration No. 44,048

4370 La Jolla Village Drive, Suite 700
San Diego, CA 92122
858.535.9001 DLC:mls
Facsimile: 858.597.1585
Date: July 12, 2005



COPY

Docket No.: 066783-0145

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Pulst, Stefan M., et al.
Appl. No. : 10/782,375
Filed : February 18, 2004
Title : PARKIN INTERACTING
POLYPEPTIDES AND METHODS
OF USE


Customer No.: 41552
Confirmation No.: 3578

Grp./A.U. : Unassigned
Examiner: : Unassigned

CERTIFICATE OF MAILING BY EXPRESS MAIL(37 CFR § 1.10)

"Express Mail" Mailing Label Number EV 540 267 677 US

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Oct 8, 2004.


Carrie Casey

RESPONSE TO NOTICE TO FILE MISSING PARTS

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We are in receipt of the Notice to File Missing Parts mailed August 13, 2004, the following are provided:

1. A copy of the Notice to File Missing Parts.
2. Declaration.
3. Power of Attorney for Patent Application by Assignee.
4. Statement Under 37 C.F.R. § 3.73(b) and a copy of the executed assignment.
5. Small Entity Statement.
6. Paper Copy of Sequence Listing, pages 1 through 14.
7. A Copy of The Sequence Listing in Computer Readable Form.
8. Statement Under 37 C.F.R. § 1.821(f) and (g).

Serial No. 10/782,375

9. Statutory Basic Filing Fee of \$395.00
10. Late Filing Fee Surcharge of \$65.00
11. Additional Claim Fee of \$256.00 (4 extra claims and 5 independent claims)
12. Return Receipt Postcard.

Please charge Deposit Account No. 502624 in the amount of \$716.00. To the extent necessary, Applicants petition for an extension of time under 37 C.F.R. 1.136. Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 502624 and please credit any excess fees to such deposit account.

Respectfully submitted,

MCDERMOTT WILL & EMERY LLP



Deborah L. Cadena
Registration No. 44,048

4370 La Jolla Village Drive, Suite 700
San Diego, CA 92122
858.535.9001 DLC:cec
Facsimile: 858.597.1585
Date: October 8, 2004



UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 12 2005

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/782,375	02/18/2004	Stefan M. Pulst	66783-145

CONFIRMATION NO. 3578

FORMALITIES LETTER



OC000000013528145

Cathryn Campbell
 McDERMOTT, WILL & EMERY
 7th Floor
 4370 La Jolla Village Drive
 San Diego, CA 92122

Date Mailed: 08/13/2004

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

*Filing Date Granted*Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.
Applicant must submit \$ 770 to complete the basic filing fee for a non-small entity. If appropriate, applicant may make a written assertion of entitlement to small entity status and pay the small entity filing fee (37 CFR 1.27).
- The oath or declaration is missing.
A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

The applicant needs to satisfy supplemental fees problems indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- Additional claim fees of \$502 as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

SUMMARY OF FEES DUE:

Total additional fee(s) required for this application is \$1402 for a Large Entity

- \$770 Statutory basic filing fee.
- \$130 Late oath or declaration Surcharge.
- Total additional claim fee(s) for this application is \$502
 - \$430 for 5 independent claims over 3.
 - \$72 for 4 total claims over 20.

Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450


*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



DECLARATION FOR PATENT APPLICATION

As the below-named inventors, we hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled PARKIN INTERACTING POLYPEPTIDES AND METHODS OF USE, the specification of which

_____ is attached hereto as Attorney Client-Matter No. _____).

X was filed on February 18, 2004, as Application Serial No. 10/782,375. (Attorney Client-Matter No. 66783-145)

and was amended on (or amended through)_____.
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to myself to be material to patentability as defined in Title 37, Code of Federal Regulations, Sec. 1.56.

Under Sec. 1.56, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or (2) It refutes, or is inconsistent with, a position the applicant takes in: (a) Opposing an argument of unpatentability relied on by the U.S. Patent and Trademark Office, or (b) Asserting an argument of patentability.


I hereby claim the benefit under Title 35, United States Code, § 119(e) of the United States provisional application(s) listed below and claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject

Inventors: Pulst and Huynh
Serial No.: 10/782,375
Filed: February 18, 2004
Page 2


matter of each of the claims of these application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status
60/448,252	February 18, 2003	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor:	Stefan M. Pulst
Inventor's signature:	
Date:	8/19/04
Residence:	Los Angeles, California 90046
Citizenship:	Germany
Mailing Address:	8125 Skyline Drive Los Angeles, California 90046

Inventors: Pulst and Huynh
Serial No.: 10/782,375
Filed: February 18, 2004
Page 3

Full name of second inventor:	Duong P. Huynh
Inventor's signature:	
Date:	3-29-04
Residence:	Long Beach, California
Citizenship:	United States of America
Mailing Address:	5953 Linden Avenue Long Beach, California 90805

POWER OF ATTORNEY FOR PATENT APPLICATION BY ASSIGNEE

Assignee Cedars-Sinai Medical Center is the owner of the entire right, title and interest of U.S. Patent Application Serial No. 10/782,375, filed on February 18, 2004, as attorney docket number 66783-145, and entitled PARKIN INTERACTING POLYPEPTIDES AND METHODS OF USE and any subsequently filed divisional, continuation, or reissue application, including international and foreign applications claiming priority thereto.

The Assignee hereby appoints the following attorneys to prosecute these applications and to transact all related business in the United States Patent and Trademark Office and any international and foreign patent offices:

CATHRYN CAMPBELL, Registration No. 31,815; DAVID A. GAY, Registration No. 39,200; ANDREA L. GASHLER, Registration No. 41,029; DEBORAH L. CADENA, Registration No. 44,048; ASTRID R. SPAIN, Registration No. 47,956; and PAMELA M. GUY, Registration No. 51,228.

Please direct all telephone calls to Cathryn Campbell at (858) 535-9001 and address all correspondence to:

CATHRYN CAMPBELL
McDERMOTT, WILL & EMERY
4370 La Jolla Village Drive
Suite 700
San Diego, California 92122

The undersigned is authorized to sign on behalf of the Assignee.

Signature:



Name (typed): Peter E. Braveman

Title:

Senior Vice President for Legal Affairs
and General Counsel

Assignee:

CEDARS-SINAI MEDICAL CENTER

Date:

8/17/04

STATEMENT UNDER 37 C.F.R. § 3.73(b)

Title of Application: PARKIN INTERACTING POLYPEPTIDES
 AND METHODS OF USE

Application Ser. No.: 10/782,375

Filed: February 18, 2004


Inventor(s): Pulst and Huynh

Attorney Client-Matter No.: 66783-145

CEDARS-SINAI MEDICAL CENTER, a non-profit organization, states that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of an assignment from the inventors of the application. A copy of the executed assignment, submitted for recording, is attached hereto as documentary evidence of the chain of title to the assignee.

The undersigned is empowered to sign this statement on behalf of the assignee.

8/17/04
Date

Name: 
Peter E. Braveman
Senior Vice President for Legal Affairs and
Title: General Counsel

CEDARS-SINAI MEDICAL CENTER
8700 Beverly Boulevard
Los Angeles, California 90048-1865

ASSIGNMENT

This Assignment is made by Stefan M. Pulst of Los Angeles, California and Duong P. Huynh of Long Beach, California, Assignors, to CEDARS-SINAI MEDICAL CENTER, Assignee, having a place of business at 8700 Beverly Boulevard, TSB 290 Los Angeles, California 90048

WHEREAS, Assignors have invented a new and useful PARKIN INTERACTING POLYPEPTIDES AND METHODS OF USE, for which an application for United States Letters Patent was filed on February 18, 2004, in the United States Patent and Trademark Office, bearing Serial No. 10/782,375 and identified as Attorney Client-Matter No: 66783-145;

WHEREAS, Assignors believe themselves to be the original inventors of the invention disclosed and claimed in said application for Letters Patent; and

WHEREAS, the parties desire to have a recordable instrument assigning an undivided part interest of Assignor's right, title and interest in and to said invention, said application and any Letters Patent that may be granted for said invention in the United States and throughout the world;

NOW, THEREFORE, in accordance with the obligations to assign the invention and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignors sell, assign, and transfer to Assignee, an undivided part interest of Assignor's right, title, and interest in and to said invention, said application, any applications entitled to benefit of priority to said application under Title 35, United States Code, Sections 120, 121 or 251, which include divisionals, continuations and reissues, and any Letters Patent that may be granted on said invention or these applications in the United States and throughout the world, including the right to file foreign applications directly in the name of the Assignee and to

Inventors: Pulst and Huynh
Serial No.: 10/782,375
Filed: February 18, 2004
Page 2 of 8

claim for any such foreign applications any priority rights to which such applications are entitled under international conventions, treaties, or otherwise.

Assignors agree that, upon request and without further compensation, but at no expense to Assignors, they and their legal representatives and assigns will do all lawful acts, including the execution of papers and the giving of testimony, that may be necessary or desirable for obtaining, sustaining, reissuing, or enforcing Letters Patent in the United States and throughout the world for said invention, and for perfecting, recording, or maintaining the title of Assignee, its successors and assigns, to said invention, said application, and any Letters Patent granted for said invention in the United States and throughout the world.

Assignors represent and warrant that they have not granted and will not grant to others any rights inconsistent with the rights as stated herein.

Assignors authorize and request that any United States or foreign Letters Patent granted for said invention, whether on said application or on any subsequently filed divisional, continuation or reissue application, be issued to Assignee, its successors and assigns, as the assignee of an undivided part interest of Assignor's interest in said invention.

Inventors: Pulst and Huynh
Serial No.: 10/782,375
Filed: February 18, 2004
Page 3 of 8

IN WITNESS WHEREOF, Assignors have executed this Assignment on the date(s) provided below.

Assignor: Stefan M. Pulst

Signature: *Stefan M. Pulst*

Date: 6-24-04


STATE OF California)

COUNTY OF Los Angeles)

On June 24, 2004, before me, June-ellen Miller personally appeared Stefan M. Pulst, ~~X~~ personally known to me - OR ~~_____~~ proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that ~~he/she/they~~ executed the same in ~~his/her/their~~ authorized capacity(ies), and that by ~~his/her/their~~ signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS by hand and official seal.

June-ellen Miller
(Signature of Notary)



Inventors: Pulst and Huynh
Serial No.: 10/782,375
Filed: February 18, 2004
Page 4 of 8

Assignor: Duong P. Huynh

Signature: 


Date: 3-29-04


STATE OF California)

COUNTY OF Los Angeles)

On 3/29/04, before me, JUNE-ELLEN MILLER personally appeared DUONG P. HUYNH, ~~personally known to me~~ - OR - ~~X~~ proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) ~~is~~ are subscribed to the within instrument and acknowledged to me that ~~he/she/they~~ executed the same in ~~his/her/their~~ authorized capacity~~(ies)~~, and that by ~~his/her/their~~ signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS by hand and official seal.


(Signature of Notary)



PATENT

Client-Matter No.: 66783-145

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Pulst and Huynh)
Serial No: 10/782,375)
Filed: February 18, 2004)
For: PARKIN INTERACTING)
POLYPEPTIDES AND METHODS)
OF USE)
_____)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SMALL ENTITY STATEMENT

The U.S. Patent and Trademark (USPTO) permits parties that establish status as a Small Entity to pay certain reduced fees (all citations to 37 C.F.R. § 1.27 except as noted). To be entitled to Small Entity Status, a party must be at least one of the following:

(1) Individual person:

An individual person, including an inventor and persons to whom an inventor has transferred some rights in the invention. § 1.27(a)(1).

(2) Small business concern:

A business concern whose number of employees, including affiliates, does not exceed 500 persons. § 1.27(a)(2) (incorporating 13 C.F.R. § 121.802).

“Business concern” means individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative. If the concern is a joint venture, participation by foreign business entities may not be more than 49%. 13 C.F.R. § 121.105.

The “number of employees” is the average number of employees, including the employees of its domestic and foreign affiliates, based on

numbers of employees for each of the pay periods for the preceding completed 12 calendar months. "Employees" includes all individuals employed on a full-time, part-time, temporary, or other basis. Part-time and temporary employees are counted the same as full-time employees. If a concern has not been in business for 12 months, use the average number of employees for each of the pay periods it has been in business. 13 C.F.R. § 121.106.

Concerns are "affiliates" of each other when one concern directly or indirectly controls or has the power to control the other, or when a third party or parties controls or has the power to control both concerns. 13 C.F.R. § 121.103(a).

(3) Nonprofit organization:

A university or other institution of higher education located in any country. § 1.27(a)(3) (ii)(A).

An organization of the type described in section 501(c)(3) of the Internal Revenue Code of 1986 and exempt from taxation under section 501(a). Also included are such organizations located in a foreign country that would qualify if it were located in this country. § 1.27(a)(3)(ii)(B),(D).

A nonprofit scientific or educational organization qualified under a nonprofit organization statute of a U.S. state. Also included are such organizations located in a foreign country that would qualify if it were located in this country. § 1.27(a)(3)(ii)(C),(D).

Please note that a license to the Government resulting from a rights determination under Executive Order 10096 does not constitute a license that would prohibit claiming Small Entity Status. Similarly, for small business concerns and nonprofit organizations, a license to a Federal agency resulting from a funding agreement with that agency under 35 U.S.C. § 202(c)(4) is not a license that would prohibit claiming Small Entity Status. § 1.27(a)(4).

I hereby assert that I am empowered to sign on behalf of the party identified below ("Party"). Persons empowered to sign include, but are not limited to, an inventor him- or herself or an authorized officer of an assignee or licensee. See § 1.27(c)(2).

I have made a determination of the Party's entitlement to Small Entity Status, including a determination that all parties holding rights in the invention qualify for Small Entity Status. § 1.27(f).

Inventors: Pulst and Huynh
Serial No.: 10/782,375
Filed: February 18, 2004
Page 3

I hereby assert that the Party has not assigned, granted, conveyed or licensed--and is under no obligation under contract or law to do so--any rights in the invention to any other party that would not qualify as a Small Entity. Separate assertions of Small Entity Status should be obtained from each party having rights to the invention.

I hereby assert that the Party is entitled to be accorded Small Entity Status by the USPTO for the application or patent identified above. § 1.27(c)(1).


I understand that Small Entity Status must be newly determined when the issue fee and each maintenance fee is due. If there is any change resulting in loss of entitlement to Small Entity Status, I acknowledge the duty to file a notification to the USPTO in this application or patent before or upon paying the fee. § 1.27(g).

I understand that Small Entity Status must be separately established in any related application, including continuation, divisional, continuation-in-part, continued prosecution application or reissue application. § 1.27(c)(4).

I understand that any attempt to establish Small Entity Status improperly, deceptively or fraudulently will be considered a fraud practiced on the USPTO and may result in abandonment of the application or jeopardize the validity and enforceability of any resulting patent. § 1.27(h).

8/19/04
Date

Name:



Peter E. Braveman

Title:

Senior Vice President for Legal Affairs
and General Counsel

CEDARS-SINAI MEDICAL CENTER
8700 Beverly Boulevard
Los Angeles, California 90048-1865

Docket No.: 066783-0145

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Pulst, Stefan M., et al. Customer No.: 41552
Appl. No. : 10/782,375 Confirmation No.: 3578
Filed : February 18, 2004
Title : PARKIN INTERACTING
POLYPEPTIDES AND METHODS
OF USE
Grp./A.U. : Unassigned
Examiner: : Unassigned

CERTIFICATE OF MAILING BY EXPRESS MAIL(37 CFR § 1.10)

"Express Mail" Mailing Label Number EV 540 267 677 US

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Oct 8, 2004.

Carrie Casey

STATEMENT UNDER 37 C.F.R. § 1.821(f) and (g)

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

I hereby state that the submission, filed in accordance with 37 C.F.R. § 1.821(g) herein does not include new matter.

Respectfully submitted,
MCDERMOTT WILL & EMERY LLP



Deborah L. Cadena
Registration No. 44,048

4370 La Jolla Village Drive, Suite 700
San Diego, CA 92122
858.535.9001 DLC:cec
Facsimile: 858.597.1585
Date: October 8, 2004

SEQUENCE LISTING

<110> Pulst, Stefan M.
Huynh, Duong P.

<120> Parkin Interacting Polypeptides and
Methods of Use

<130> 66783-145

<140> US 10/782,375

<141> 2004-12-18

<150> 60/448,252

<151> 2003-02-18

<160> 15

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1453

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (272)...(955)

<221> misc_feature

<222> (1)...(1453)

<223> n = A,T,C or G

<400> 1

agtcctcaac gaggggtcca gtgtaggcag tgacaggcac atagctgttg agctcagcga	60
ggcggggctg tgatacctcg gcccggtttt taccgatgtc ctctcccgc aggtagaact	120
gggaggaaag atcagcccac tgggcagtgc cctgggtcatg tagggtaaca gccttgaccc	180
caccaaggat gatgttctta gcgatctcca cgcccaggcc ccgcaggcct gataccagga	240
cactggatgt ctggagccgc ttcattgcct c atg gcc caa cac ata cag ctg	292
Met Ala Gln His Ile Gln Leu	
1 5	

ccg gga gta aag gcc ctc gtc tat gtc tgc ttc act gcc gtt ctt ggc	340
Pro Gly Val Lys Ala Leu Val Tyr Val Cys Phe Thr Ala Val Leu Gly	
10 15 20	

cat tcc gtt ggt tgg cac cga ggg cac ttc gga caa cac gga ctg ggc	388
His Ser Val Gly Trp His Arg Gly His Phe Gly Gln His Gly Leu Gly	
25 30 35	

agg gga gca gtt aga acc cgg ctt tgg atc agg ccc gga cac gcg acg	436
Arg Gly Ala Val Arg Thr Arg Leu Trp Ile Arg Pro Gly His Ala Thr	

40	45	50	55	
ttt ctt gga cag cgg cga gct gga cat caa tgc cgg ttc ccc ggg tcg				484
Phe Leu Gly Gln Arg Arg Ala Gly His Gln Cys Arg Phe Pro Gly Ser				
	60	65	70	
cgc cgc cgc caa ctc ctc aag gag ccg aag cca agc ccg gcc gca ccc				532
Arg Arg Arg Gln Leu Leu Lys Glu Pro Lys Pro Ser Pro Ala Ala Pro				
	75	80	85	
tcc tcc ttc tcc tcc tcc ccg ccg cct ggg ccg cct aga atc gcc gct				580
Ser Ser Phe Ser Ser Ser Pro Pro Pro Gly Pro Pro Arg Ile Ala Ala				
	90	95	100	
gcc gcc ttc tcc tcc ccc ggc cgt tgt ggt tgt ggt tgt ccc tgc cac				628
Ala Ala Phe Ser Ser Pro Gly Arg Cys Gly Cys Gly Cys Pro Cys His				
	105	110	115	
ctc ctt aca gcc gag ccg ccg aca caa gat ggc gga cgc ttg agc ctg				676
Leu Leu Thr Ala Glu Pro Pro Thr Gln Asp Gly Gly Arg Leu Ser Leu				
	120	125	130	135
ggg ccg gaa caa aac ctt ggg ccc cac ccc cag aaa ccc gga tgc aag				724
Gly Pro Glu Gln Asn Leu Gly Pro His Pro Gln Lys Pro Gly Cys Lys				
	140	145	150	
cgg gcc gcg cct act tat gaa tca tgc ata aag ttc cct act cgg ttg				772
Arg Ala Ala Pro Thr Tyr Glu Ser Cys Ile Lys Phe Pro Thr Arg Leu				
	155	160	165	
cga ttc att cgg tta gaa gtg gaa cag cac cac ctg gtg gac att gtg				820
Arg Phe Ile Arg Leu Glu Val Glu Gln His His Leu Val Asp Ile Val				
	170	175	180	
gca gta aca acg aaa aca ggt aaa aca gag gcc acg cct cat gga atg				868
Ala Val Thr Thr Lys Thr Gly Lys Thr Glu Ala Thr Pro His Gly Met				
	185	190	195	
cga cta atg aat gaa ttg ttg cag cca ggc tgt caa gga agc gaa gaa				916
Arg Leu Met Asn Glu Leu Leu Gln Pro Gly Cys Gln Gly Ser Glu Glu				
	200	205	210	215
aaa ccg tta agg cca tgc ttc ctg att ata agt tat gca tgaagttgag				965
Lys Pro Leu Arg Pro Cys Phe Leu Ile Ile Ser Tyr Ala				
	220	225		
tggttggttag caacaaccag caaccagaaa gcagatgtta aaacatggaa gccacacacc				1025
cccattcatg aatnaatgat gatcttgacg gggcccggaa gccaaggaga cccaggccac				1085
aacttacttc atgaataatg catgaggccc agtgggttg gataaaaagg gcacgcccgc				1145
ctattgctgc atctaataca ctgtaagcag ggaaatgggg ctgctgcagg gaaaacacac				1205
tctcccaggc cctgaataat gaattatgct gctgcagtag ctcaacctgg aaactcagag				1265
aggtaagaa aggttcacc caatttatga attatgcata aggcgaagaa acaccaaga				1325
ctgccctgcc cctcatttac ataaatatta tactagcatt taccatctca cttctaggaa				1385

tactagtata tcgctcacac ctcatatcct ccctactatg cctagaagga ataatactat 1445
cgctgtcg 1453

<210> 2
<211> 228
<212> PRT
<213> Homo sapiens

<400> 2
Met Ala Gln His Ile Gln Leu Pro Gly Val Lys Ala Leu Val Tyr Val
1 5 10 15
Cys Phe Thr Ala Val Leu Gly His Ser Val Gly Trp His Arg Gly His
20 25 30
Phe Gly Gln His Gly Leu Gly Arg Gly Ala Val Arg Thr Arg Leu Trp
35 40 45
Ile Arg Pro Gly His Ala Thr Phe Leu Gly Gln Arg Arg Ala Gly His
50 55 60
Gln Cys Arg Phe Pro Gly Ser Arg Arg Arg Gln Leu Leu Lys Glu Pro
65 70 75 80
Lys Pro Ser Pro Ala Ala Pro Ser Ser Phe Ser Ser Ser Pro Pro Pro
85 90 95
Gly Pro Pro Arg Ile Ala Ala Ala Phe Ser Ser Pro Gly Arg Cys
100 105 110
Gly Cys Gly Cys Pro Cys His Leu Leu Thr Ala Glu Pro Pro Thr Gln
115 120 125
Asp Gly Gly Arg Leu Ser Leu Gly Pro Glu Gln Asn Leu Gly Pro His
130 135 140
Pro Gln Lys Pro Gly Cys Lys Arg Ala Ala Pro Thr Tyr Glu Ser Cys
145 150 155 160
Ile Lys Phe Pro Thr Arg Leu Arg Phe Ile Arg Leu Glu Val Glu Gln
165 170 175
His His Leu Val Asp Ile Val Ala Val Thr Thr Lys Thr Gly Lys Thr
180 185 190
Glu Ala Thr Pro His Gly Met Arg Leu Met Asn Glu Leu Leu Gln Pro
195 200 205
Gly Cys Gln Gly Ser Glu Glu Lys Pro Leu Arg Pro Cys Phe Leu Ile
210 215 220
Ile Ser Tyr Ala
225

<210> 3
<211> 684
<212> DNA
<213> Homo sapiens

<400> 3
atggcccaac acatacagct gccgggagta aaggccctcg tctatgtctg cttcactgcc 60
gttcttggcc attccgttgg ttggcaccga gggcacttcg gacaacacgg actgggcagg 120
ggagcagtta gaacccggct ttggatcagg cccggacacg cgacgtttct tggacagcgg 180
cgagctggac atcaatgccg gttccccggg tcgcgccgcc gccaaactct caaggagccg 240
aagccaagcc cggccgcacc ctctctcttc tctctctccc cgccgcctgg gccgcctaga 300
atcgccgctg ccgccttctc ctccccgggc cgttgtggtt gtggttggtc ctgccacctc 360
cttacagccg agccgccgac acaagatggc ggacgcttga gcctggggcc ggaacaaaac 420

cttgggcccc	acccccagaa	acccggatgc	aagcgggccc	cgcctactta	tgaatcatgc	480
ataaagttcc	ctactcggtt	gcgattcatt	cggttagaag	tggaacagca	ccacctggtg	540
gacattgtgg	cagtaacaac	gaaaacaggt	aaaacagagg	ccacgcctca	tggaatgcga	600
ctaatgaatg	aattgttgca	gccaggctgt	caaggaagcg	aagaaaaacc	gttaaggcca	660
tgcttctga	ttataagtta	tgca				684

<210> 4
<211> 958
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1) ... (958)
<223> n = A,T,C or G

<400> 4						
gaattcgcg	ccgcgtcgac	ctccttctcc	tcctccccgc	cgcctgngcc	gcctagaatc	60
gccgctgcc	ccttctctcc	ccccggccgt	tgtggttggt	gttgtccctg	ccacctcctt	120
acagccgagc	cgccgacaca	agatggcgga	cgctgagcct	ggggccggaa	caaaaccttg	180
ggccccaccc	ccagaaaccc	ggatgcaagc	gggcccgcgc	tacttatgaa	tcatgcataa	240
agttccctac	tcggttgcga	ttcattcggt	tagaagtgga	acagcaccac	ctggtggaca	300
ttgtggcagt	aacaacgaaa	acaggtnaaa	cagaagccac	gcctcatgga	atgcgactaa	360
tgaatgaatt	gttgagacca	ggctgtcaag	gaagcgaaaa	aaaaaccggt	aaggccatgc	420
ttcctgatta	taagttatgc	atgaagttga	gtgggttggt	gacttaacaa	ccagcaacca	480
gaaagcagat	gttaaaacat	ggaagccaca	cacccccatt	catgaataat	gatgatcttg	540
caggggcccc	gaagccaagg	agacccaggc	cacaacttac	ttcatgaata	atgcatgagg	600
cccagtgggt	tggaataaaa	ggggcacgcc	cgcctattgc	tgcattctaat	acactgtaag	660
cagggaaatg	gggctgctgc	agggaaaaca	cactctccca	ggtcctgaat	aatgaattat	720
gctgctgcag	tagctcaacc	tggaactca	gagaggtcaa	gaaagggtcc	acccaattta	780
tgaattatgc	ataaggcgaa	gaaacaccca	agactgccct	gcccctcatt	tacataaata	840
ttatactagc	atttaccatc	tcacttctag	gaatactagt	atatcgctca	cacctcatat	900
cctccctact	atgcctagaa	ggaataatac	tatcgctgtc	gacgcgggcc	gcgaattc	958

<210> 5
<211> 2453
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (266) ... (1534)

<400> 5						
agagcactgg	ggaccgagac	ccggcaccac	ctcccgggtcc	gccctccagg	gaaaacggga	60
aaactagcaa	gagctagcaa	gaactagcaa	gagcttgaac	aaacgcctgg	actcagattg	120
gaagactgct	catttgtcta	ctgcctcatt	cctggaaatt	gcactggaac	tgtctgatta	180
agaaaaacag	aataattctg	aaagaaagaa	aacaaagaaa	aacatactcc	agaattccta	240
atagaacact	tcacctgaac	ctaaa	atg gtg agc gag	agt cac cat gag gcc		292
			Met Val Ser Glu Ser His His Glu Ala			
		1		5		

ctg gca gcc ccg cct gtc acc act gtc gcg act gtt ctg cca agc aat	340
---	-----

Leu	Ala	Ala	Pro	Pro	Val	Thr	Thr	Val	Ala	Thr	Val	Leu	Pro	Ser	Asn	
10					15					20					25	
gcc	aca	gag	cca	gcc	agt	cct	gga	gaa	gga	aag	gaa	gat	gca	ttt	tct	388
Ala	Thr	Glu	Pro	Ala	Ser	Pro	Gly	Glu	Gly	Lys	Glu	Asp	Ala	Phe	Ser	
				30					35					40		
aag	ctg	aag	gag	aag	ttt	atg	aat	gag	ttg	cat	aaa	att	cca	ttg	cca	436
Lys	Leu	Lys	Glu	Lys	Phe	Met	Asn	Glu	Leu	His	Lys	Ile	Pro	Leu	Pro	
			45					50					55			
ccg	tgg	gcc	tta	att	gca	ata	gcc	ata	gtc	gca	gtc	ctt	tta	gtc	ctg	484
Pro	Trp	Ala	Leu	Ile	Ala	Ile	Ala	Ile	Val	Ala	Val	Leu	Leu	Val	Leu	
		60					65					70				
acc	tgc	tgc	ttt	tgt	atc	tgt	aag	aaa	tgt	ttg	ttc	aaa	aag	aaa	aac	532
Thr	Cys	Cys	Phe	Cys	Ile	Cys	Lys	Lys	Cys	Leu	Phe	Lys	Lys	Lys	Asn	
	75					80					85					
aag	aag	aag	gga	aag	gaa	aaa	gga	ggg	aag	aat	gcc	att	aac	atg	aaa	580
Lys	Lys	Lys	Gly	Lys	Glu	Lys	Gly	Gly	Lys	Asn	Ala	Ile	Asn	Met	Lys	
90					95					100					105	
gat	gta	aaa	gac	tta	ggg	aag	acg	atg	aaa	gat	cag	gcc	ctc	aag	gat	628
Asp	Val	Lys	Asp	Leu	Gly	Lys	Thr	Met	Lys	Asp	Gln	Ala	Leu	Lys	Asp	
				110					115					120		
gat	gat	gct	gaa	act	gga	ttg	aca	gat	gga	gaa	gaa	aaa	gaa	gaa	ccc	676
Asp	Asp	Ala	Glu	Thr	Gly	Leu	Thr	Asp	Gly	Glu	Glu	Lys	Glu	Glu	Pro	
			125					130					135			
aaa	gaa	gag	gag	aaa	ctg	gga	aaa	ctt	cag	tat	tca	ctg	gat	tat	gat	724
Lys	Glu	Glu	Glu	Lys	Leu	Gly	Lys	Leu	Gln	Tyr	Ser	Leu	Asp	Tyr	Asp	
	140						145					150				
ttc	caa	aat	aac	cag	ctg	ctg	gta	ggg	atc	att	cag	gct	gcc	gaa	ctg	772
Phe	Gln	Asn	Asn	Gln	Leu	Leu	Val	Gly	Ile	Ile	Gln	Ala	Ala	Glu	Leu	
	155					160					165					
ccc	gcc	ttg	gac	atg	ggg	ggc	aca	tct	gat	cct	tac	gtg	aaa	gtg	ttt	820
Pro	Ala	Leu	Asp	Met	Gly	Gly	Thr	Ser	Asp	Pro	Tyr	Val	Lys	Val	Phe	
170					175					180					185	
ctg	cta	cct	gat	aag	aag	aag	aaa	ttt	gag	aca	aaa	gtc	cac	cga	aaa	868
Leu	Leu	Pro	Asp	Lys	Lys	Lys	Lys	Phe	Glu	Thr	Lys	Val	His	Arg	Lys	
				190					195					200		
acc	ctt	aat	cct	gtc	ttc	aat	gag	caa	ttt	act	ttc	aag	gta	cca	tac	916
Thr	Leu	Asn	Pro	Val	Phe	Asn	Glu	Gln	Phe	Thr	Phe	Lys	Val	Pro	Tyr	
			205					210					215			
tcg	gaa	ttg	ggt	ggc	aaa	acc	cta	gtg	atg	gct	gta	tat	gat	ttt	gat	964
Ser	Glu	Leu	Gly	Gly	Lys	Thr	Leu	Val	Met	Ala	Val	Tyr	Asp	Phe	Asp	

220	225	230	
cgt ttc tct aag cat gac atc att gga gaa ttt aaa gtc cct atg aac			1012
Arg Phe Ser Lys His Asp Ile Ile Gly Glu Phe Lys Val Pro Met Asn			
235	240	245	
aca gtg gat ttt ggc cat gta act gag gaa tgg cgt gac ctg caa agt			1060
Thr Val Asp Phe Gly His Val Thr Glu Glu Trp Arg Asp Leu Gln Ser			
250	255	260	265
gct gag aag gaa gag caa gag aaa ttg ggt gat atc tgc ttc tcc ctt			1108
Ala Glu Lys Glu Glu Gln Glu Lys Leu Gly Asp Ile Cys Phe Ser Leu			
270	275	280	
cgc tac gta cct act gct ggt aag ctg act gtt gtc att ctg gag gca			1156
Arg Tyr Val Pro Thr Ala Gly Lys Leu Thr Val Val Ile Leu Glu Ala			
285	290	295	
aag aac ctg aag aag atg gat gtg ggt ggc tta tcc gat cct tat gtg			1204
Lys Asn Leu Lys Lys Met Asp Val Gly Gly Leu Ser Asp Pro Tyr Val			
300	305	310	
aag att cat ctg atg cag aat ggt aag agg ctg aag aag aaa aag aca			1252
Lys Ile His Leu Met Gln Asn Gly Lys Arg Leu Lys Lys Lys Lys Thr			
315	320	325	
aca att aaa aag aac aca ctt aac ccc tac tac aat gag tca ttc agc			1300
Thr Ile Lys Lys Asn Thr Leu Asn Pro Tyr Tyr Asn Glu Ser Phe Ser			
330	335	340	345
ttt gaa gta cct ttt gaa caa atc cag aaa gtg cag gtg gtg gta act			1348
Phe Glu Val Pro Phe Glu Gln Ile Gln Lys Val Gln Val Val Val Thr			
350	355	360	
gtt ttg gac tat gac aag att ggc aag aac gat gcc atc ggc aaa gtc			1396
Val Leu Asp Tyr Asp Lys Ile Gly Lys Asn Asp Ala Ile Gly Lys Val			
365	370	375	
ttt gtg ggc tac aac agc acc ggc gcg gag ctg cga cac tgg tca gac			1444
Phe Val Gly Tyr Asn Ser Thr Gly Ala Glu Leu Arg His Trp Ser Asp			
380	385	390	
atg ctg gcc aac ccc agg cga cct att gcc cag tgg cac acc ctg cag			1492
Met Leu Ala Asn Pro Arg Arg Pro Ile Ala Gln Trp His Thr Leu Gln			
395	400	405	
gta gag gag gaa gtt gat gcc atg ctg gcc gtc aag aag taa			1534
Val Glu Glu Glu Val Asp Ala Met Leu Ala Val Lys Lys *			
410	415	420	
aggaaagaag aagcctttct gcatttgccc atatagtgt ctttagccag tatctgtaaa			1594
tacctcagta atatgggtcc tttcattttt ccagccatgc attcctaaca caattcagtg			1654
gtacttgga tctgttttta atttgcacaa atttaaattgt agagagcccc taagtccttc			1714


```

atcataccac tgcctccaa atctactctt cttttaagca atatgatgtg tagatagagc 1774
atgaatgaaa ttattttattg tatcacactg ttgtatatat cagtatgcta aagattttatt 1834
tctagtttgt gtattttgtat gttgtaagcg tttcctaata tgtgtatatc tagatgtttt 1894
taataagatg ttctatttta aactatgtaa attgactgag atataggaga gctgataata 1954
tattatacgg taaatatagt atcgtctgca ttccagcaaa aatatcaact cgtaaggcac 2014
tagtacagtt aaactgacat cttaaaggac aacttaaacc tgagctttct attgaatcat 2074
ttgagtacca agataaactt acaccacata cttggtgggt gaatccaatt ttgtagaatt 2134
cctacacagg caaaatagca tgatctgagc agcagcatcc aggctgacct caaggaagca 2194
tagccacaaa acagaatagc acctgtctgt acatatttac aaagctaaaa taatggcttc 2254
actcttatat ttgaggaagc aactgaacag gagtcaatga tttcatatta ctgcatatag 2314
aataacaaca aggtgttccg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg cacatttggt 2374
tggggatggg ggagaagaag ctaaggggag aagtcaacat ttatgaaata ttgcctgact 2434
atttaaaaaa aaaaaaaaaa 2453

```

<210> 6

<211> 422

<212> PRT

<213> Homo sapiens

<400> 6

```

Met Val Ser Glu Ser His His Glu Ala Leu Ala Ala Pro Pro Val Thr
 1          5          10          15
Thr Val Ala Thr Val Leu Pro Ser Asn Ala Thr Glu Pro Ala Ser Pro
          20          25          30
Gly Glu Gly Lys Glu Asp Ala Phe Ser Lys Leu Lys Glu Lys Phe Met
          35          40          45
Asn Glu Leu His Lys Ile Pro Leu Pro Pro Trp Ala Leu Ile Ala Ile
          50          55          60
Ala Ile Val Ala Val Leu Leu Val Leu Thr Cys Cys Phe Cys Ile Cys
65          70          75          80
Lys Lys Cys Leu Phe Lys Lys Lys Asn Lys Lys Lys Gly Lys Glu Lys
          85          90          95
Gly Gly Lys Asn Ala Ile Asn Met Lys Asp Val Lys Asp Leu Gly Lys
          100          105          110
Thr Met Lys Asp Gln Ala Leu Lys Asp Asp Asp Ala Glu Thr Gly Leu
          115          120          125
Thr Asp Gly Glu Glu Lys Glu Glu Pro Lys Glu Glu Glu Lys Leu Gly
          130          135          140
Lys Leu Gln Tyr Ser Leu Asp Tyr Asp Phe Gln Asn Asn Gln Leu Leu
145          150          155          160
Val Gly Ile Ile Gln Ala Ala Glu Leu Pro Ala Leu Asp Met Gly Gly
          165          170          175
Thr Ser Asp Pro Tyr Val Lys Val Phe Leu Leu Pro Asp Lys Lys Lys
          180          185          190
Lys Phe Glu Thr Lys Val His Arg Lys Thr Leu Asn Pro Val Phe Asn
          195          200          205
Glu Gln Phe Thr Phe Lys Val Pro Tyr Ser Glu Leu Gly Gly Lys Thr
          210          215          220
Leu Val Met Ala Val Tyr Asp Phe Asp Arg Phe Ser Lys His Asp Ile
225          230          235          240
Ile Gly Glu Phe Lys Val Pro Met Asn Thr Val Asp Phe Gly His Val
          245          250          255
Thr Glu Glu Trp Arg Asp Leu Gln Ser Ala Glu Lys Glu Glu Gln Glu

```

	260		265		270										
Lys	Leu	Gly	Asp	Ile	Cys	Phe	Ser	Leu	Arg	Tyr	Val	Pro	Thr	Ala	Gly
	275						280					285			
Lys	Leu	Thr	Val	Val	Ile	Leu	Glu	Ala	Lys	Asn	Leu	Lys	Lys	Met	Asp
	290						295				300				
Val	Gly	Gly	Leu	Ser	Asp	Pro	Tyr	Val	Lys	Ile	His	Leu	Met	Gln	Asn
305					310					315					320
Gly	Lys	Arg	Leu	Lys	Lys	Lys	Lys	Thr	Thr	Ile	Lys	Lys	Asn	Thr	Leu
			325					330					335		
Asn	Pro	Tyr	Tyr	Asn	Glu	Ser	Phe	Ser	Phe	Glu	Val	Pro	Phe	Glu	Gln
			340					345					350		
Ile	Gln	Lys	Val	Gln	Val	Val	Val	Thr	Val	Leu	Asp	Tyr	Asp	Lys	Ile
	355						360				365				
Gly	Lys	Asn	Asp	Ala	Ile	Gly	Lys	Val	Phe	Val	Gly	Tyr	Asn	Ser	Thr
	370					375					380				
Gly	Ala	Glu	Leu	Arg	His	Trp	Ser	Asp	Met	Leu	Ala	Asn	Pro	Arg	Arg
385					390					395					400
Pro	Ile	Ala	Gln	Trp	His	Thr	Leu	Gln	Val	Glu	Glu	Glu	Val	Asp	Ala
			405					410						415	
Met	Leu	Ala	Val	Lys	Lys										
			420												

<210> 7

<211> 5103

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (254) ... (1549)

<400> 7

agaaggcgga	gcctacctct	catcaggacc	agtctgactg	cacctgcatt	cttagctcag	60
agcatccccg	gagcatctta	agagctgagc	gcagctgaca	actaggggcc	ggaccgtcgc	120
aggaggcgtc	cgctggatac	cttccccctt	ccttgaccta	gagctctaca	gctgctgcct	180
cggctactgac	cgagggttcc	cagagctgtc	tcaccattgc	aaaaacgtta	tagcaacagc	240
ctctgattac	gac atg gct gag atc acc aat atc cga cct agc ttt gat					289
	Met Ala Glu Ile Thr Asn Ile Arg Pro Ser Phe Asp					
	1	5	10			
gtg tca ccg gtg gtg gcc ggc ctc atc ggg gcc tct gtg ctg gtg gtg						337
Val Ser Pro Val Val Ala Gly Leu Ile Gly Ala Ser Val Leu Val Val						
	15	20	25			
tgt gtc tcg gtg acc gtc ttt gtc tgg tca tgc tgc cac cag cag gca						385
Cys Val Ser Val Thr Val Phe Val Trp Ser Cys Cys His Gln Gln Ala						
	30	35	40			
gag aag aag cac aag aac cca cca tac aag ttt att cac atg ctc aaa						433
Glu Lys Lys His Lys Asn Pro Pro Tyr Lys Phe Ile His Met Leu Lys						
	45	50	55	60		
ggc atc agc ata tac cca gag acc ctc agc aac aag aag aaa atc atc						481

Gly	Ile	Ser	Ile	Tyr	Pro	Glu	Thr	Leu	Ser	Asn	Lys	Lys	Lys	Ile	Ile		
				65					70					75			
aaa	gtg	cgg	aga	gac	aaa	gat	ggg	cct	ggg	agg	gaa	ggg	gga	cgt	agg		529
Lys	Val	Arg	Arg	Asp	Lys	Asp	Gly	Pro	Gly	Arg	Glu	Gly	Gly	Arg	Arg		
			80					85					90				
aac	ctg	ttg	gtg	gac	gca	gca	gag	gct	ggc	ctg	cta	agc	cga	gac	aaa		577
Asn	Leu	Leu	Val	Asp	Ala	Ala	Glu	Ala	Gly	Leu	Leu	Ser	Arg	Asp	Lys		
		95					100					105					
gat	ccc	agg	ggg	cct	agc	tct	gga	tct	tgt	ata	gac	caa	tta	ccc	atc		625
Asp	Pro	Arg	Gly	Pro	Ser	Ser	Gly	Ser	Cys	Ile	Asp	Gln	Leu	Pro	Ile		
	110					115				120							
aaa	atg	gac	tat	ggg	gaa	gaa	cta	agg	agc	cct	att	aca	agc	ctg	acc		673
Lys	Met	Asp	Tyr	Gly	Glu	Glu	Leu	Arg	Ser	Pro	Ile	Thr	Ser	Leu	Thr		
125					130					135					140		
cct	ggg	gag	agc	aaa	acc	acc	tct	cca	tca	tct	cca	gag	gag	gat	gtc		721
Pro	Gly	Glu	Ser	Lys	Thr	Thr	Ser	Pro	Ser	Ser	Pro	Glu	Glu	Asp	Val		
				145				150						155			
atg	cta	gga	tcc	ctc	acc	ttc	tca	gtg	gac	tat	aac	ttc	ccg	aaa	aaa		769
Met	Leu	Gly	Ser	Leu	Thr	Phe	Ser	Val	Asp	Tyr	Asn	Phe	Pro	Lys	Lys		
			160					165					170				
gcc	ctg	gtg	gtg	aca	atc	cag	gag	gcc	cac	ggg	ctg	cca	gtg	atg	gat		817
Ala	Leu	Val	Val	Thr	Ile	Gln	Glu	Ala	His	Gly	Leu	Pro	Val	Met	Asp		
		175					180					185					
gac	cag	acc	cag	gga	tct	gac	ccc	tac	atc	aaa	atg	acc	atc	ctt	cct		865
Asp	Gln	Thr	Gln	Gly	Ser	Asp	Pro	Tyr	Ile	Lys	Met	Thr	Ile	Leu	Pro		
	190					195				200							
gac	aaa	cgg	cat	cgg	gtg	aag	acc	aga	gtg	ctg	cgg	aag	acc	ctg	gac		913
Asp	Lys	Arg	His	Arg	Val	Lys	Thr	Arg	Val	Leu	Arg	Lys	Thr	Leu	Asp		
205					210					215					220		
cct	gtg	ttt	gac	gag	acc	ttc	acc	ttc	tat	gtc	atc	ccc	tac	agc	cag		961
Pro	Val	Phe	Asp	Glu	Thr	Phe	Thr	Phe	Tyr	Val	Ile	Pro	Tyr	Ser	Gln		
				225					230					235			
ctg	cag	gac	ctg	gtg	ctg	cac	ttc	ctt	gtc	ctc	agc	ttt	gac	cgc	ttc		1009
Leu	Gln	Asp	Leu	Val	Leu	His	Phe	Leu	Val	Leu	Ser	Phe	Asp	Arg	Phe		
			240					245					250				
tct	cgg	gat	gat	gtc	att	ggc	gag	gtc	atg	gtg	cca	ctg	gca	ggg	gtg		1057
Ser	Arg	Asp	Asp	Val	Ile	Gly	Glu	Val	Met	Val	Pro	Leu	Ala	Gly	Val		
		255					260					265					
gac	ccc	agc	aca	ggc	aag	gta	caa	ctg	acc	agg	gac	atc	atc	aaa	agg		1105
Asp	Pro	Ser	Thr	Gly	Lys	Val	Gln	Leu	Thr	Arg	Asp	Ile	Ile	Lys	Arg		

270	275	280	
aat atc cag aag tgc atc agc aga ggg gag ctc cag gtg tct ctg tca			1153
Asn Ile Gln Lys Cys Ile Ser Arg Gly Glu Leu Gln Val Ser Leu Ser			
285	290	295	300
tat cag cct gtg gca cag aga atg aca gtg gtg gtc ctc aaa gcc aga			1201
Tyr Gln Pro Val Ala Gln Arg Met Thr Val Val Val Leu Lys Ala Arg			
	305	310	315
cac ttg ccg aag atg gat atc acc ggt ctc tca ggt aat cct tat gtc			1249
His Leu Pro Lys Met Asp Ile Thr Gly Leu Ser Gly Asn Pro Tyr Val			
	320	325	330
aag gtg aac gtc tac tac ggc aga aag cgc att gcc aag aag aaa acc			1297
Lys Val Asn Val Tyr Tyr Gly Arg Lys Arg Ile Ala Lys Lys Lys Thr			
	335	340	345
cat gtg aag aag tgc act ttg aac ccc atc ttc aat gaa tct ttc atc			1345
His Val Lys Lys Cys Thr Leu Asn Pro Ile Phe Asn Glu Ser Phe Ile			
	350	355	360
tac gac atc ccc act gac ctc ctg cct gat atc agc atc gag ttc ctc			1393
Tyr Asp Ile Pro Thr Asp Leu Leu Pro Asp Ile Ser Ile Glu Phe Leu			
	365	370	375
gtt atc gac ttc gat cgc acc acc aag aat gag gtg gtg ggg agg ctg			1441
Val Ile Asp Phe Asp Arg Thr Thr Lys Asn Glu Val Val Gly Arg Leu			
	385	390	395
atc ctg ggg gca cac agt gtc aca gcc agt ggt gct gaa cac tgg aga			1489
Ile Leu Gly Ala His Ser Val Thr Ala Ser Gly Ala Glu His Trp Arg			
	400	405	410
gag gtc tgc gag agc ccc cgc aag cct gtg gcc aag tgg cac agt ctg			1537
Glu Val Cys Glu Ser Pro Arg Lys Pro Val Ala Lys Trp His Ser Leu			
	415	420	425
agc gag tac taa tcctgttctt ctctcctcta atccccgggg gccaaagctgg			1589
Ser Glu Tyr *			
430			
ggagggatgt ggaggggaaa aagatgacag agaagtggac tccaaacctc atttttagttg			1649
tagaagaaaa tttcttacia aacaaattcc acaaagaaca ccctatatga ccacagctgc			1709
agatcagttc ttagcaatga tggttttttt tctgctttgc aaggcgctag aatcttttat			1769
tttactttat tttttttgag gtggagtttc gctcttggtg cccgggctgg agtgcaatgg			1829
tgagatctca actcactgca acctctgccc ttcagggttca agtgattctc ctccctcagc			1889
ctcccaagta gctgggatta caggcaccca cgagcatgcc cggctaattt tttgtatttt			1949
cagtagagat ggggtttcacc atgttggccca ggctgggtctc gaattccaga cctcaggtga			2009
tccacccgcc tcggcctccc aaagtgtctgg gattacaggt gcgagccacc gtgcccggcc			2069
tctgggttttg ttttggtttt tttttttaat gggggacaaa agagagggaa agaccctat			2129
aatctatat ataacaatgt aaccatatac ttgcatgtct aatacaaact gaagaaatta			2189
gcctaactgc caatatcaag ttgcagattt taatccatgg aaattgtgtt ttgtgctgaa			2249

ttgtatttgc	tgattacctg	aaattggctt	ctttttattg	ggcttctctg	gagaatttct	2309
cccactcccc	acctctgcag	aagaaaattt	tgctcttata	aaacctcatg	ttttcatcat	2369
tcctatcttt	tctttttatt	gcctcttata	tctctgctct	ttgacctcaa	ggtctagagg	2429
tctgcagtaa	gccaagaaac	aaaggtgggg	tggatgaggg	aaggtttgca	ggagaaagag	2489
gaattgagaa	atgggggtatt	tttgctatca	gctcttctgc	tatgaagtag	taaaaggcag	2549
tctataatta	actgacagac	ctaactgaag	cacagagaa	acatcagact	tatgcatcca	2609
agacatcaga	acttggattt	tatcaaactt	gatgacttct	ctaaaaggag	ctttggaaac	2669
ttcaaattca	gctataggat	agtaccaatg	aacacatcca	gctgatccca	aaagctgttt	2729
tcaggtataa	ggacaaggag	aggagacaag	tgacgacagc	cattccccct	tgcagctatc	2789
tactgtagtg	acagccattt	cttggttgat	gggttggaag	tcatcagagg	tttgaagaat	2849
tacactggcc	tttgtttttc	tggaaatgcc	gaccatggag	atgctttaga	gtcttctaaa	2909
atagcttaga	tgttgtaatg	aggttagctt	tgcttcataa	aacaggggcc	ctcagaagtt	2969
ctccttaaat	ttttcaataa	aaatttagct	cttaaaaaaa	taacagtgtg	actgagtga	3029
tgaagataag	ttggattctt	tcagagcatt	cttttcctca	aaacgagctg	cataattctt	3089
ggaatttatg	tcttaccaca	tgggtggagg	atgggggaac	tacaggatgc	aattcttctt	3149
ctaccaatgg	gcaatagagg	ttgagagaga	ttcagcatct	ttctgggatt	agaattcaag	3209
tctctttact	cctacagcag	ctgcgtctcc	aacgttgaga	ctttgcagat	ggcacagact	3269
ccatggataa	taggtaaact	tggggccggg	cgcagtggct	cacgcctgta	atccccgtat	3329
tttgggaggg	cgaggtggaa	agatcgcttg	agcccaggag	ttcaagacca	gcctgggcta	3389
catgacgaaa	ctccatctct	atcaaaaaata	caaaaaatta	actaggtgtg	gtgctgcacg	3449
cctgtgggtcc	cagctattca	ggaggctgag	gtgggaggat	catttgagcc	cagaggtaga	3509
ggctgcagtg	agccatgatc	atgccactgc	actctgggct	gggtaacaga	gtgagatcct	3569
gtctcaaaaa	ttaattaatt	aattaattaa	aataaactag	gtaaacttgg	ataggcagta	3629
gatatttttg	cccacctgag	gaggatctca	gtcaagctgt	tgcttaacag	cttgatccag	3689
ggcgtgaaag	gttagttgag	actgaagtgt	tcacttccat	agaagaacat	cacttttaac	3749
cttgcttttg	cgaagggagt	cggaaagctg	agtctctatg	gacggggggg	tgatcttgct	3809
ttcagtgttc	cctcagcttt	tgtggattta	aaaccattct	gctcccccta	aaccttttgt	3869
ttgatttcag	cccattgtct	tgacaatgca	gagcaattct	gagcagtcac	aaagcctact	3929
ctctgttctt	gtccctgcca	acccccaccc	cccataatct	gactcacaac	ttcaccatca	3989
gttgggggtca	taccactagt	ctctgtccta	taccccatga	aatgtaaata	ctgtatcata	4049
agtagaagaa	aataattttt	gttttctaaa	aatgcatttt	gagatagttt	aatgtaaatc	4109
tgacaggagc	attctgaagc	cccattagga	aaaaatttaa	atggttcctc	ttcatcgcct	4169
taatgtctaa	agatcagaaa	tcgctgagca	aaccgccttt	tgtttccttc	ccagaaacaa	4229
tgcaaaacaa	caggtggaga	tagtctggtc	tttgccctgc	tgtgtgtgcc	tctgtagctc	4289
ctcctgacaa	acgtctggga	aaacagcctc	acccactctc	cctctctctt	ccccatttcc	4349
ttgtagcttt	attccttgca	tctttgggtc	tactgagcag	tgggtgctga	ggtgacaggg	4409
gaggaaccag	ttgttctgtg	gcctaggaac	tgccctcagt	tctttgccag	aaaaaggcaa	4469
agaggcggac	agtgcagggc	tcctccctcc	tacctcaggc	ctgatccatc	gtgcccttga	4529
ctttgccgtc	tcaaagtttc	ttagctgact	ttggctttca	catttgttct	ttccagagct	4589
aactgataag	agtggaggag	gaatgccttc	tcctaagagt	cagttgaaag	aaagacaaga	4649
gagtcacatc	ttagcttttg	cacaaggcat	tcgtggtcag	gaataggtta	gggaatggtc	4709
acttctgatt	ttccaacagt	tgctccttct	ctgaagagat	cttgattcct	ttgggaagac	4769
aagaattttt	cttaataaca	aaggtcactt	tatgagttat	tccttctttc	agttcatctc	4829
actggagcac	agccaagatg	gacatgttta	tggacagtgc	tctagatgtg	aaaacagata	4889
gaactggttt	gtgggacagg	ggcagcttgc	tcaggagagg	gaataacgca	ggtccctttt	4949
cttgggaagg	ttgtactatg	gccatgacag	tgacattgcc	ctcaccatga	tcctctcca	5009
aagtggttgt	ctttctttac	cttgtgtctt	ctcttgtaaa	aatgaaactc	aaaaataaaa	5069
taaatgtgtc	aaatttcgaa	aaaaaaaaaa	aaaa			5103

<210> 8

<211> 431

<212> PRT

<213> Homo sapiens

<400> 8

Met	Ala	Glu	Ile	Thr	Asn	Ile	Arg	Pro	Ser	Phe	Asp	Val	Ser	Pro	Val
1				5				10					15		
Val	Ala	Gly	Leu	Ile	Gly	Ala	Ser	Val	Leu	Val	Val	Cys	Val	Ser	Val
			20					25					30		
Thr	Val	Phe	Val	Trp	Ser	Cys	Cys	His	Gln	Gln	Ala	Glu	Lys	Lys	His
		35					40					45			
Lys	Asn	Pro	Pro	Tyr	Lys	Phe	Ile	His	Met	Leu	Lys	Gly	Ile	Ser	Ile
	50					55					60				
Tyr	Pro	Glu	Thr	Leu	Ser	Asn	Lys	Lys	Lys	Ile	Ile	Lys	Val	Arg	Arg
65					70					75				80	
Asp	Lys	Asp	Gly	Pro	Gly	Arg	Glu	Gly	Gly	Arg	Arg	Asn	Leu	Leu	Val
				85					90					95	
Asp	Ala	Ala	Glu	Ala	Gly	Leu	Leu	Ser	Arg	Asp	Lys	Asp	Pro	Arg	Gly
			100					105					110		
Pro	Ser	Ser	Gly	Ser	Cys	Ile	Asp	Gln	Leu	Pro	Ile	Lys	Met	Asp	Tyr
		115					120					125			
Gly	Glu	Glu	Leu	Arg	Ser	Pro	Ile	Thr	Ser	Leu	Thr	Pro	Gly	Glu	Ser
	130					135					140				
Lys	Thr	Thr	Ser	Pro	Ser	Ser	Pro	Glu	Glu	Asp	Val	Met	Leu	Gly	Ser
145					150					155					160
Leu	Thr	Phe	Ser	Val	Asp	Tyr	Asn	Phe	Pro	Lys	Lys	Ala	Leu	Val	Val
				165					170					175	
Thr	Ile	Gln	Glu	Ala	His	Gly	Leu	Pro	Val	Met	Asp	Asp	Gln	Thr	Gln
			180					185					190		
Gly	Ser	Asp	Pro	Tyr	Ile	Lys	Met	Thr	Ile	Leu	Pro	Asp	Lys	Arg	His
	195					200						205			
Arg	Val	Lys	Thr	Arg	Val	Leu	Arg	Lys	Thr	Leu	Asp	Pro	Val	Phe	Asp
	210					215					220				
Glu	Thr	Phe	Thr	Phe	Tyr	Val	Ile	Pro	Tyr	Ser	Gln	Leu	Gln	Asp	Leu
225					230				235						240
Val	Leu	His	Phe	Leu	Val	Leu	Ser	Phe	Asp	Arg	Phe	Ser	Arg	Asp	Asp
				245					250					255	
Val	Ile	Gly	Glu	Val	Met	Val	Pro	Leu	Ala	Gly	Val	Asp	Pro	Ser	Thr
			260					265					270		
Gly	Lys	Val	Gln	Leu	Thr	Arg	Asp	Ile	Ile	Lys	Arg	Asn	Ile	Gln	Lys
	275					280						285			
Cys	Ile	Ser	Arg	Gly	Glu	Leu	Gln	Val	Ser	Leu	Ser	Tyr	Gln	Pro	Val
	290					295					300				
Ala	Gln	Arg	Met	Thr	Val	Val	Val	Leu	Lys	Ala	Arg	His	Leu	Pro	Lys
305					310					315					320
Met	Asp	Ile	Thr	Gly	Leu	Ser	Gly	Asn	Pro	Tyr	Val	Lys	Val	Asn	Val
				325					330					335	
Tyr	Tyr	Gly	Arg	Lys	Arg	Ile	Ala	Lys	Lys	Lys	Thr	His	Val	Lys	Lys
			340					345					350		
Cys	Thr	Leu	Asn	Pro	Ile	Phe	Asn	Glu	Ser	Phe	Ile	Tyr	Asp	Ile	Pro
			355				360					365			
Thr	Asp	Leu	Leu	Pro	Asp	Ile	Ser	Ile	Glu	Phe	Leu	Val	Ile	Asp	Phe
	370					375						380			
Asp	Arg	Thr	Thr	Lys	Asn	Glu	Val	Val	Gly	Arg	Leu	Ile	Leu	Gly	Ala
385					390					395					400
His	Ser	Val	Thr	Ala	Ser	Gly	Ala	Glu	His	Trp	Arg	Glu	Val	Cys	Glu

	405		410		415									
Ser	Pro	Arg	Lys	Pro	Val	Ala	Lys	Trp	His	Ser	Leu	Ser	Glu	Tyr
		420						425					430	

<210> 9
<211> 15
<212> PRT
<213> Homo sapiens

<400> 9
His Gln Gln Ala Glu Lys Lys Gln Lys Asn Pro Pro Tyr Lys Phe
1 5 10 15

<210> 10
<211> 16
<212> PRT
<213> Homo sapiens

<400> 10
Lys Val Arg Arg Asp Lys Asp Gly Pro Arg Arg Glu Ser Gly Arg Gly
1 5 10 15

<210> 11
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> forward primer

<400> 11
Lys Val Arg Arg Asp Lys Asp Gly Pro Arg Arg Glu Ser Gly Arg Gly
1 5 10 15

<210> 12
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> reverse primer

<400> 12
Thr Thr Thr Cys Cys Thr Thr Thr Ala Cys Thr Thr Cys Thr Thr Gly
1 5 10 15
Ala Cys Gly

<210> 13
<211> 21
<212> PRT
<213> Artificial Sequence

<220>

<223> reverse primer

<400> 13

Thr Gly Ala Ala Gly Gly Ala Cys Thr Thr Ala Gly Gly Gly Gly Cys
1 5 10 15
Thr Cys Thr Cys Thr
20

<210> 14

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> forward primer

<400> 14

Gly Ala Gly Gly Gly Thr Thr Cys Cys Cys Ala Gly Ala Gly Cys Thr
1 5 10 15
Gly Thr Cys Thr
20

<210> 15

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> reverse primer

<400> 15

Cys Ala Cys Ala Thr Cys Cys Cys Thr Cys Cys Cys Cys Ala Gly Cys
1 5 10 15
Thr Thr Gly



EV 540267677 US

Mailing Label
Label 11-F June 2002

UNITED STATES POSTAL SERVICE®

Post Office To Addressee

ORIGIN (POSTAL USE ONLY)

PO ZIP Code	Day of Delivery <input type="checkbox"/> Next <input type="checkbox"/> Second	Flat Rate Envelope <input type="checkbox"/>
Date In Mo. Day Year	<input type="checkbox"/> 12 Noon <input type="checkbox"/> 3 PM	Postage \$
Time In <input type="checkbox"/> AM <input type="checkbox"/> PM	Military <input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	Return Receipt Fee
Weight lbs. ozs.	Int'l Alpha Country Code	COD Fee Insurance Fee
No Delivery <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday	Acceptance Clerk Initials	Total Postage & Fees \$

DELIVERY (POSTAL USE ONLY)

Delivery Attempt	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Mo. Day		
Delivery Attempt	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Mo. Day		
Delivery Date	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Mo. Day		
<input type="checkbox"/> WAIVER OF SIGNATURE (Domestic Only) Additional merchandise insurance is void if waiver of signature is requested. If delivery employee judges that article can be left in secure location and/or addressee's agent, delivery employee's signature constitutes valid proof of delivery.		
NO DELIVERY <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday		

CUSTOMER USE ONLY

METHOD OF PAYMENT:

Express Mail Corporate Acct. No.

Federal Agency Acct. No. or
Postal Service Acct. No.

FROM: (PLEASE PRINT)

PHONE 858 535 9001

MCDERMOTT WILL & EMERY LLP
4370 LA JOLLA VILLAGE DR STE 700
SAN DIEGO CA 92122-1252

TO: (PLEASE PRINT)

PHONE ()

MAIL STOP MERRILL PARKS
COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA VA 22313-1450

PRESS HARD.

You are making 3 copies.

FOR PICKUP OR TRACKING CALL 1-800-222-1811 www.usps.com



135/ 200

F:02 1:12

Applicant: Pulst, Stefan M., et al.

Docket No. 066783-0145

Title: PARKIN INTERACTING POLYPEPTIDES AND METHODS OF USE

Serial/Reg./Patent No. 10/782,375

Date Sent: 10/8/2004 ☐ Hand Carried ☐ Fax ☐ Electronic ☐ Cert. of Mailing ☒ Express Mail No. EV 540 267 677 US☐ Transmittal LetterNew Patent App ☐ Utility ☐ Design ☐ Cont. ☐ CIP ☐ Div. ☐ PCT ☐ RCE ☐ Prov☒ Other: Paper Copy of Sequence Listing Pages 1 to 14; A Copy of the Sequence Listing in Computer Readable Form and Statement Under 37 C.F.R. § 1.821(f) and (g)

pages of Specification

pages of Claims

pages of Abstract

pages of Formal/Informal Drawings

☒ Small Entity Statement☒ Declaration/Power of Attorney☐ Recordation of Assignment/Security Agreement☐ Information Disclosure Statement

Form PTO 1449

copies of cited references

☐ Preliminary Amendment☒ Response to Missing Parts Notice and A Copy of the Missing Parts☐ Resp. to Notice to Correct App. Papers☐ Certified Copy of Priority Doc.☐ Claim for Convention Priority☐ Response/Amendment to Office Action of☐ Request for month Extension of Time☐ Req. for Approval of Drawing Amendments☐ Req. for Oral Hearing☐ Not. of Appeal ☐ Appeal Brief ☐ Reply Brief☐ Rule 312 Amendment/Letter☐ Req. for Acknowledgement of Cited Art☐ Issue Fee☐ Publication Fee☐ Req. for Certificate of Correction☐ Maintenance Fee for years after grant☐ Fee Address Indication Form☐ Terminal Disclaimer☐ Petition to Commissioner☐ Status Inquiry☒ Other Statement Under 37 C.F.R. § 3.73(b) and a copy of the executed assignment.

Check for \$

☒ Charge Deposit Acct. 502624\$

716.00

Atty Init.

DLC

Tkpr. #

7312

Secy. or PL:

CCasey

CMS Descrip.: \$395.00 - Basic Filing Fee \$65.00 - Surcharge Fee \$256.00 - excess claims

THE PATENT AND TRADEMARK OFFICE DATE STAMPED HEREON IS ACKNOWLEDGEMENT THAT THE ITEMS, CHECKED ABOVE, WERE RECEIVED BY THE PTO ON THE DATE STAMPED.



UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 12 2005

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
10/782,375	02/18/2004	Stefan M. Pulst	66783-145

Cathryn Campbell
 McDERMOTT, WILL & EMERY
 7th Floor
 4370 La Jolla Village Drive
 San Diego, CA 92122

CONFIRMATION NO. 3578

ABANDONMENT/TERMINATION
 LETTER



OC000000016019444

Date Mailed: 05/13/2005

NOTICE OF ABANDONMENT UNDER 37 CFR 1.53 (f) OR (g)

The above-identified application is abandoned for failure to timely or properly reply to the Notice to File Missing Parts (Notice) mailed on 08/13/2004.

- No reply was received.

If a complete reply to the notice was previously filed by applicant within the time period set forth in the notice, applicant may request for reconsideration of the holding of abandonment within 2 months from the mailing of this notice of abandonment by filing a petition to withdraw the holding of abandonment under 37 CFR 1.181(a). No petition fee is required. The petition must be accompanied by a true copy of the originally filed reply and the item(s) identified in one of the following:

1. A properly itemized date-stamped postcard receipt (see MPEP § 503);
2. If the originally filed reply included a certificate of mailing or transmission in compliance with 37 CFR 1.8(a), a copy of the certificate of mailing or transmission and a statement in compliance with 37 CFR 1.8(b) (see MPEP §§ 512); or
3. If the reply was filed via Express Mail, a submission satisfying the requirements of 37 CFR 1.10(e) including, for example, a copy of the Express Mail mailing label showing the "date-in" (see MPEP § 513).

Any petition to withdraw the holding of abandonment should be directed to OIPE.

If applicant did not previously file a complete reply within the time period set forth in the notice, applicant may file a petition to revive the application under 37 CFR 1.137.

Under 37 CFR 1.137(a), a petition requesting the application be revived on the grounds of **UNAVOIDABLE DELAY** must be filed promptly after the applicant becomes aware of the abandonment and such petition must be accompanied by: (1) an adequate showing of the cause of unavoidable delay; (2) the required reply to the above-identified Notice; (3) the petition fee set forth in 37 CFR 1.17(l); and (4) a terminal disclaimer if required by 37 CFR 1.137(d). See MPEP § 711.03(c) and Form PTO/SB/61.

Under 37 CFR 1.137(b), a petition requesting the application be revived on the grounds of **UNINTENTIONAL DELAY** must be filed promptly after applicant becomes aware of the abandonment and such petition must be accompanied by: (1) a statement that the entire delay was unintentional; (2) the required reply to the above-

identified Notice; (3) the petition fee set forth in 37 CFR 1.17(m); and (4) a terminal disclaimer if required by 37 CFR 1.137(d). See MPEP § 711.03(c) and Form PTO/SB/64.

Any questions concerning petitions to revive should be directed to the "Office of Petitions" at (571) 272-3282.

A copy of this notice MUST be returned with the reply.

213 L
Office of Initial Patent Examination (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE